Sangeetha Bollini

Director, Preclinical Operations

Sangeetha Bollini is Director of Preclinical Operations. She has over 20 years of experience in various aspects of drug development, including protein engineering, assay development, regulatory operations, portfolio management, quality and CMC. Prior to joining Tallac, she was Director of Program Management at ALX Oncology, where she led Bioanalytical PK, ADA, and biomarker assays for preclinical and clinical studies, supported CMC analytical and cell-based assays, quality, and Regulatory Operations for multidisciplinary teams. Before ALX, Sangeetha was Assay Development Head at Pfizer overseeing preclinical and clinical assays across multiple platforms, in oncology, cardiovascular, CNS, ocular, and other therapeutic areas, spanning discovery research to late phase trials. Her role also included overseeing quality and regulatory submissions for preclinical studies.